Retatrutide vs Tirzepatide vs Semalgutide -By Polypeptide.ltd
Authoritative source：PubChem Again, research into retatrutide peptide is ongoing. But data so far show that retatrutide may help people lose even more weight than other Tirzepatide and Semaglutide. According to previous research on people, here are some of the clinical trials results: Novo Nordisk’s semaglutide was found to reduce body weight, on average, by around 15%, or about 34 pounds, after 68 weeks. And Lilly’s other weight loss drug, tirzepatide, was shown to reduce body weight, by 22.5% on
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
average, or about 52 pounds, after 72 weeks. The experimental drug, retatrutide, helped people lose, on average, about 24% of their body weight, the equivalent of about 58 pounds,after 48 weeks. However, this is a limited-time effect, and the actual Retatrutide benefits could be even better. Phase three trials would reveal the full potential and long-term effects, making it easy for people to trust it. To be sure, these are not direct comparisons because the drugs were not compared in a head-to-head clinical trial. What benefits we can expect from Retatrutide powder are weight loss and type 2 diabetes treatment. But Retatrutide has the potential to work faster and more effectively than Tirzepatide and Semaglutide. Phase II trial In recent results from its Phase II trial (NCT04881760), data showed that after 48 weeks, in the retatrutide dosage 1mg, 4mg, 8mg, and 12mg groups, -8.7%, -17.1%, -22.8%, and -24.2% percentage change in body weight was recorded. Furthermore, a weight reduction of 15% or more was recorded in 60% of subjects in the study. With regards to safety, the most common adverse events were of a gastrointestinal nature, and thus retatrutide’s safety profile was on par with other incretin-based therapies. A Phase III trial (TRIUMPH-3; NCT05882045) began in May, studying the effects of retatrutide in patients with severe obesity and established cardiovascular disease, and is estimated to end in November 2025.
Reference citations [1]Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators.”Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.”N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26.PMID: 37366315 [2]Doggrell SA.”Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?”Expert Opin Investig Drugs. 2023 May;32(5):355-359. doi: 10.1080/13543784.2023.2206560. Epub 2023 Apr 24.PMID: 37086147 [3]Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T.”Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.”Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26.PMID: 37385280 [4]Harris E.”Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss.”JAMA. 2023 Jul 25;330(4):306. doi: 10.1001/jama.2023.12055.PMID: 37405802 [5]Urva S, O’Farrell L, Du Y, Loh MT, Hemmingway A, Qu H, Alsina-Fernandez J, Haupt A, Milicevic Z, Coskun T.”The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.”Diabetes Obes Metab. 2023 Sep;25(9):2784-2788. doi: 10.1111/dom.15167. Epub 2023 Jun 13.PMID: 37311727 [6]Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., & Milicevic, Z. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet (London, England), 400(10366), 1869–1881. https://doi.org/10.1016/S0140-6736(22)02033-5. [7]Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A.”Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.”Lancet. 2018 Nov 17;392(10160):2180-2193. doi: 10.1016/S0140-6736(18)32260-8. Epub 2018 Oct 4.PMID: 30293770 [8]”Lilly’s phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight” (Press release). Eli Lilly. 26 June 2023. Retrieved 3 July 2023. [9]Constantino, Annika Kim (26 June 2023). “Eli Lilly experimental obesity drug could beat rivals in total weight loss for patients”. CNBC. Retrieved 3 July 2023. [10]Ajit Regmi, William Roell.”Differentiation of human subcutaneous adipocytes and measurement of lipolytic function induced by GIP or LY3437943.” https://doi.org/10.1016/j.xpro.2023.102304 [11]Clifford J. Bailey, Peter R. Flatt , J. Michael Conlon.”An update on peptide-based therapies for type 2 diabetes and obesity.” https://doi.org/10.1016/j.peptides.2023.170939 [12]Peter M. Clifton.”Cutting Edge Developments in Diabetes.” Diabetology 2023, 4(3), 278-281;
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
https://doi.org/10.3390/diabetology4030024. [13]Rajmohan Seetharaman and Swarnima Pandit. “Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape?” From the journal Journal of Basic and Clinical Physiology and Pharmacology.https://doi.org/10.1515/jbcpp-2023-0172
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/